CAS: 942947-95-7; 2-Amino-5-Bromo-4-Chloro-3-Nitropyridine

该化合物是一种卤化硝基丙烯衍生物,在制药和农用化学合成方面有很大用途,其溴和氯替代成分增强了核生殖器替代反应的回活动性,而硝基化合物组则促进了进一步的功能化.该化合物是构建复杂的热循环框架的多功能中间体,特别是在生物活性分子的开发方面.在标准储存条件下和明确界定的再活动特征下,其稳定性成为医药化学和材料科学应用的可靠建筑块.由于存在多个电子生物场,因此可以进行选择性的修改,并允许有选择的合成途径.

英文名称2-Amino-5-Bromo-4-Chloro-3-Nitropyridine
中文名称2-氨基-5-溴-4-氯-3-硝基吡啶
IUPAC名称5-bromo-4-chloro-3-nitropyridin-2-amine
其它别名2-氨基-3-硝基-4-氯-5-溴吡啶; 2-Amino-5-Bromo-4-Chloro-3-Nitropyridine; 5-Bromo-4-Chloro-3-Nitropyridin-2-Amine; 5-Bromo-4-Chloro-3-Nitro-Pyridin-2-Ylamine
CAS编号942947-95-7
MFCD编号:MFCD11110693
EINECS号:103-324-1
分子式:C5H3BrClN3O2分子量:252.45
产品CID: 1992930
产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物

相似结构搜索
InChIKey: BLGCPXIDEMLKMS-UHFFFAOYSA-N
InChI=1S/C5H3BrClN3O2/c6-2-1-9-5(8)4(3(2)7)10(11)12/h1H,(H2,8,9)
计算化学: 氢键受体数4.0氢键供体数1.0可旋转键数1.0

相似化合物

6980-08-1 6945-68-2 37660-64-3

MSDS等安全信息

GHS象形图
GHS符号GHS07 & GHS05;
注释: Exclamation mark & Corrosion
危险类别急性毒性类别4(吸入)
急性毒性类别4(经皮)
急性毒性类别4(经口)
特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼损伤类别1
警示词Danger(危险)
危险描述H332 |吸入有害.
H312 |皮肤接触有害.
H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H318 |造成严重眼损伤.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险品标志Xi

欧盟法规

C&L通报

上下游产品

CAS号6980-08-1 2-氨基-3-硝基-4-氯吡啶 | CAS号942947-94-6 2-氨基-4-氯-5-溴吡啶 | CAS号19798-80-2 2-氨基-4-氯吡啶

合成工艺路线路线简述

6980-08-1 = 942947-95-7
反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Acetonitrile; 1 H,80 °C
标题:Preparation Of Substituted 1H-Imidazo[4,5-B]Pyridin-2(3H)-Ones And Their Use As Glun2B Receptor Modulators
参考文献:World Intellectual Property Organization]

942947-94-6 = 942947-95-7
反应条件:1.1 Reagents: Sulfuric Acid Solvents: Water; < 10 °C; 15 Min,5 - 10 °C; 55 °C1.2 Reagents: Nitric Acid Solvents: Water; 55 - 60 °C; 30 Min,55 °C; 55 °C -> Rt1.3 Reagents: Sodium Hydroxide Solvents: Water; Ph 7
标题:Imidazo[4,5-B]Pyridine Derivatives As Inhibitors Of Aurora Kinases: Lead Optimization Studies Toward The Identification Of An Orally Bioavailable Preclinical Development Candidate
作者:Bavetsias,Vassilios; Large,Jonathan M.; Sun,Chongbo; Bouloc,Nathalie; Kosmopoulou,Magda; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2010 卷标:53(14) 页码:5213-5228]

1976019-50-7 = 942947-95-7
反应条件:1.1 Reagents: Sulfuric Acid Solvents: Water; Rt; 2.5 H,40 °C; 40 °C -> Rt1.2 Reagents: Water; Neutralized,Cooled
标题:2-Phenyl-3H-Imidazo[4,5-B]Pyridine Derivatives As Inhibitors Or Mammalian Tyrosine Kinase Ror1 Activity And Their Preparation
参考文献:World Intellectual Property Organization]

= 942947-95-7 [标题:Reaction Conditions
标题:Preparation Of 2,3-Diamino-4-Bromopyridine
参考文献:China]

6980-08-1 = 942947-95-7
反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Acetonitrile; 1 H,80 °C
标题:Preparation Of Imidazopyridines As Inhibitors Of Aurora Kinase And/or Flt3
参考文献:World Intellectual Property Organization]

6980-08-1 = 942947-95-7
反应条件:1.1 Reagents: N-Bromosuccinimide Solvents: Acetonitrile; 1 H,80 °C
标题:Optimization Of Imidazo[4,5-B]Pyridine-Based Kinase Inhibitors: Identification Of A Dual Flt3/aurora Kinase Inhibitor As An Orally Bioavailable Preclinical Development Candidate For The Treatment Of Acute Myeloid Leukemia
作者:Bavetsias,Vassilios; Crumpler,Simon; Sun,Chongbo; Avery,Sian; Atrash,Butrus; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2012 卷标:55(20) 页码:8721-8734]

942947-94-6 = 942947-95-7
反应条件:1.1 Reagents: Sulfuric Acid,Nitric Acid; 0 °C -> 55 °C; 1 H,55 °C1.2 Reagents: Sodium Hydroxide; Ph 7
标题:Imidazopyridine Derivative And Pharmaceutical Composition Comprising Same As Active Ingredient
参考文献:Korea]

942947-94-6 = 942947-95-7
反应条件:1.1 Reagents: Sulfuric Acid,Nitric Acid Solvents: Water; 0 °C; 0 °C -> 55 °C; 1 H,55 °C1.2 Reagents: Sodium Hydroxide Solvents: Water; Ph 7
标题:Preparation Of Imidazopyridine Derivative As Protein Kinase Inhibitors
参考文献:World Intellectual Property Organization]

1976019-50-7 = 942947-95-7
反应条件:1.1 Reagents: Sulfuric Acid; Rt; 2.5 H,40 °C
标题:2-Phenylimidazo[4,5-B]Pyridin-7-Amine Derivatives Used As Inhibitors Of Mammalian Tyrosine Kinase Ror1 Activity And Their Preparation
参考文献:United States]

942947-94-6 = 942947-95-7
反应条件:1.1 Reagents: Sulfuric Acid; -5 °C1.2 Reagents: Fuming Nitric Acid; 5 Min,< 0 °C; 2 H,0 °C -> 50 °C; 1 H,50 °C1.3 Reagents: Water; Cooled1.4 Reagents: Ammonia; Ph 7.3
标题:Discovery And Analgesic Evaluation Of 8-Chloro-1,4-Dihydropyrido[2,3-B]Pyrazine-2,3-Dione As A Novel Potent D-Amino Acid Oxidase Inhibitor
作者:Xie,Dongsheng; Lu,Jun; Xie,Jin; Cui,Junjun; Li,Teng-Fei; Et Al
参考文献:European Journal Of Medicinal Chemistry 日期:2016 卷标:117 页码:19-32]

942947-94-6 = 942947-95-7
反应条件:1.1 Reagents: Sulfuric Acid Solvents: Water; 15 Min,-10 °C1.2 Reagents: Nitric Acid Solvents: Water; 55 - 60 °C; 30 Min,55 °C; 55 °C -> Rt1.3 Reagents: Sodium Hydroxide Solvents: Water; Ph 7,Cooled
标题:Preparation Of Imidazopyridines As Enzyme Inhibitors,Especially Aurora Kinase Inhibitors,For Treating Cell Proliferative Diseases
参考文献:World Intellectual Property Organization

📜2-氨基-4-氯吡啶置于n-溴代丁二酰亚胺(Nbs),硫酸,硝酸体系中,用乙腈作为反应溶剂,化学反应 2.17H,反应生成 2-氨基-5-溴-4-氯-3-硝基吡啶
参考文献:咪唑并[4,5-B]吡啶类激酶抑制剂的优化:鉴定双 Flt3/aurora 激酶抑制剂作为治疗急性髓系白血病的口服生物可利用临床前开发候选药物
标题:咪唑并[4,5-B]吡啶类激酶抑制剂的优化:鉴定双 Flt3/aurora 激酶抑制剂作为治疗急性髓系白血病的口服生物可利用临床前开发候选药物
摘要:对基于咪唑并[4,5-B]吡啶的系列极光激酶抑制剂进行优化,鉴定出 6-Chloro-7-(4-(4-Chlorobenzyl)Pirazin-1-yl)-2-(1,3-Dimethyl-1 H-Pyrazol-4-yl)-3 H-Imidazo[4,5-B]Pyridine (27E),一种强效的 Aurora 激酶抑制剂 (Aurora-A K D = 7.5 Nm,Aurora-B K D = 48 Nm),Flt3 激酶 (K D = 6.2 Nm) 和 Flt3 突变体,包括 Flt3-Itd (K D = 38 Nm) 和 Flt3(D835Y) (K D = 14 Nm).flt3-Itd 引起组成型 Flt3 激酶激活,在 20-35% 的成人和 15% 的急性髓性白血病 (Aml) 患儿中检测到,这两个年龄组的预后都很差.在体内环境中,27E在口服给药后强烈抑制flt3
DOI:10.1021/jm300952S